{"id":"b4","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypertension"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":{"setId":"15f7da52-16ab-4f7e-bd77-bdabe0d565b9","title":"COXSACKIE (COXSACKIE B1, B4) LIQUID [BIOACTIVE NUTRITIONAL, INC.]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"B4 acts as a potent inhibitor of the enzyme responsible for the breakdown of a key neurotransmitter, leading to increased levels of this neurotransmitter in the brain. This results in improved mood and reduced symptoms of depression. The exact mechanism of action is complex and involves multiple molecular pathways.","oneSentence":"B4 is a medication that works by inhibiting the action of a specific enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:39:23.921Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Obsessive-compulsive disorder"}]},"trialDetails":[{"nctId":"NCT07235059","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-20","conditions":"Chronic Kidney Disease","enrollment":112},{"nctId":"NCT05614739","phase":"PHASE1","title":"FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-01-12","conditions":"Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms","enrollment":535},{"nctId":"NCT07226843","phase":"PHASE1","title":"A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02","conditions":"Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma","enrollment":360},{"nctId":"NCT04657068","phase":"PHASE1, PHASE2","title":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Artios Pharma Ltd","startDate":"2021-01-27","conditions":"Advanced Cancer, Metastatic Cancer, Ovarian Cancer","enrollment":442},{"nctId":"NCT06485245","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2025-04-22","conditions":"MASH","enrollment":80},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07467447","phase":"PHASE2","title":"Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-15","conditions":"Obesity","enrollment":300},{"nctId":"NCT07125261","phase":"PHASE1","title":"BHV-7000 Responsive Neurostimulation System (RNS) Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2025-10-07","conditions":"Epilepsy, Seizures","enrollment":5},{"nctId":"NCT02264678","phase":"PHASE1, PHASE2","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-10-31","conditions":"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer","enrollment":357},{"nctId":"NCT07415031","phase":"PHASE2","title":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","status":"NOT_YET_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2026-05-16","conditions":"Solid Tumors","enrollment":170},{"nctId":"NCT03819465","phase":"PHASE1","title":"A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-27","conditions":"Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":175},{"nctId":"NCT02499328","phase":"PHASE1, PHASE2","title":"Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-06","conditions":"Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck","enrollment":340},{"nctId":"NCT01516580","phase":"PHASE3","title":"Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-12","conditions":"B-cell Non Hodgkin Lymphoma, Mature B-cell Leukemia Burkitt-type","enrollment":482},{"nctId":"NCT07355673","phase":"NA","title":"The Influence of Isolation Techniques in Gingival Irritation During an In-office Bleaching","status":"COMPLETED","sponsor":"University of Santiago de Compostela","startDate":"2025-05-15","conditions":"Gingival Irritation","enrollment":30},{"nctId":"NCT06977880","phase":"PHASE1","title":"A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants","status":"RECRUITING","sponsor":"Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)","startDate":"2025-02-19","conditions":"Healthy","enrollment":80},{"nctId":"NCT06400472","phase":"PHASE1","title":"A Study of LY4170156 in Participants With Selected Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-05-20","conditions":"Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms","enrollment":495},{"nctId":"NCT05542121","phase":"NA","title":"Rehab CARES In USA: Clinical Trial","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2022-06-01","conditions":"Stroke, Hemiplegia","enrollment":27},{"nctId":"NCT04656535","phase":"EARLY_PHASE1","title":"AB154 Combined With AB122 for Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2021-04-21","conditions":"Glioblastoma","enrollment":46},{"nctId":"NCT05006794","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-09-15","conditions":"Solid Malignancies","enrollment":145},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT06239116","phase":"PHASE1, PHASE2","title":"A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment","status":"RECRUITING","sponsor":"Rhythm Pharmaceuticals, Inc.","startDate":"2024-03-05","conditions":"Hypothalamic Obesity, Prader-Willi Syndrome, PWS","enrollment":150},{"nctId":"NCT05182073","phase":"PHASE1","title":"FT576 in Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Fate Therapeutics","startDate":"2021-11-10","conditions":"Multiple Myeloma, Myeloma","enrollment":31},{"nctId":"NCT06980090","phase":"NA","title":"Neural Mechanisms of Interpersonal Expectations on Negative Affect","status":"RECRUITING","sponsor":"Trustees of Dartmouth College","startDate":"2025-09-01","conditions":"Negative Affectivity, Non-invasive Brain Stimulation, Placebo Effect","enrollment":190},{"nctId":"NCT06625710","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects","status":"COMPLETED","sponsor":"GemVax & Kael","startDate":"2024-10-08","conditions":"Neuro-Degenerative Disease","enrollment":59},{"nctId":"NCT04561362","phase":"PHASE1, PHASE2","title":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"BicycleTx Limited","startDate":"2020-07-17","conditions":"Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms","enrollment":329},{"nctId":"NCT04931654","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-09-28","conditions":"Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":136},{"nctId":"NCT05676931","phase":"PHASE2","title":"Study With Various Immunotherapy Treatments in Participants With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-02-21","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT04972825","phase":"NA","title":"AIR-B4: Mind the Gap","status":"ACTIVE_NOT_RECRUITING","sponsor":"Health Resources and Services Administration (HRSA)","startDate":"2021-07-29","conditions":"Autism Spectrum Disorder, Neurodevelopmental Disorders","enrollment":308},{"nctId":"NCT04428281","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-08-19","conditions":"Angelman Syndrome","enrollment":74},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT03708328","phase":"PHASE1","title":"A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-10-15","conditions":"Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC)","enrollment":134},{"nctId":"NCT07055321","phase":"PHASE1","title":"A Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants","status":"COMPLETED","sponsor":"Ethris GmbH","startDate":"2023-11-29","conditions":"Healthy Subjects","enrollment":73},{"nctId":"NCT03972306","phase":"PHASE1","title":"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-08-12","conditions":"Multiple Sclerosis (MS)","enrollment":134},{"nctId":"NCT05811026","phase":"NA","title":"Efficacy of Periorbital Rejuvenation With a 1927 nm Diode Laser Treatment","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2023-03-15","conditions":"Laser, Periorbital","enrollment":20},{"nctId":"NCT06617546","phase":"PHASE1","title":"SAD and MAD Study of FTX-101 in Healthy Male Subjects","status":"TERMINATED","sponsor":"Find Therapeutics","startDate":"2024-10-14","conditions":"Healthy Volunteers","enrollment":49},{"nctId":"NCT01804790","phase":"PHASE3","title":"Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-01","conditions":"Cancer of the Rectum","enrollment":461},{"nctId":"NCT02329847","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-03-11","conditions":"Hematologic Neoplasms","enrollment":144},{"nctId":"NCT06306196","phase":"PHASE2","title":"Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2024-04-04","conditions":"Hepatitis E Virus Infection","enrollment":1040},{"nctId":"NCT05380687","phase":"NA","title":"Time Course of Neuro-ventilatory Efficiency During a Spontaneous Breathing Training","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2022-06-15","conditions":"Ventilator Weaning, Respiration, Artificial, Respiratory Muscles","enrollment":1},{"nctId":"NCT03192280","phase":"NA","title":"Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-06-19","conditions":"Skin Inflammation","enrollment":12},{"nctId":"NCT06503952","phase":"","title":"Impact of Uterine Immune Profiling and Personalized Treatments in Patients Receiving a Single Blastocyst: a Matched Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Matricelab Innove","startDate":"2025-01-15","conditions":"Infertility, Success Rate of Assisted Reproductive Therapy, Single Embryo Transfer","enrollment":340},{"nctId":"NCT02488408","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2014-10-22","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":122},{"nctId":"NCT04972838","phase":"NA","title":"AIR-B4: Remaking Recess (RR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Health Resources and Services Administration (HRSA)","startDate":"2021-07-11","conditions":"Autism Spectrum Disorder, Neurodevelopmental Disorders","enrollment":264},{"nctId":"NCT06034860","phase":"PHASE1","title":"Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types","status":"TERMINATED","sponsor":"Molecular Templates, Inc.","startDate":"2023-11-01","conditions":"Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma","enrollment":15},{"nctId":"NCT04899349","phase":"PHASE2","title":"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-04-06","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT06480305","phase":"NA","title":"Impact of Evening Snacks and Pre-Breakfast Intake on Sleep, Heart Rate Variability, and Stress Markers in Healthy Males.","status":"RECRUITING","sponsor":"Riphah International University","startDate":"2024-08-02","conditions":"Circadian Rhythm","enrollment":80},{"nctId":"NCT06019065","phase":"PHASE1","title":"A SAD, MAD and Food Effect Study to Evaluate the Safety, Tolerability, PK, and PD of AJA001 in Healthy Subjects","status":"COMPLETED","sponsor":"AJNA Australia Pty Ltd","startDate":"2023-09-13","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT06451731","phase":"NA","title":"Rehabilitation of Post-stroke Aphasia by Targeting Phonological, and Lexico-semantic Deficits With Speech Output Tasks","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2015-06-01","conditions":"Aphasia, Acquired, Stroke, Anomia","enrollment":44},{"nctId":"NCT04117711","phase":"PHASE1, PHASE2","title":"Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia","status":"COMPLETED","sponsor":"Applied Therapeutics, Inc.","startDate":"2019-06-21","conditions":"Classic Galactosemia","enrollment":114},{"nctId":"NCT04812262","phase":"PHASE1","title":"A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD","status":"COMPLETED","sponsor":"Neuraly, Inc.","startDate":"2021-02-24","conditions":"Overweight and Obesity, Type2 Diabetes, NAFLD","enrollment":255},{"nctId":"NCT05507515","phase":"PHASE1","title":"A Phase 1 Study of ONO-2020 in Healthy Participants","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2022-07-29","conditions":"Healthy Volunteers","enrollment":132},{"nctId":"NCT05435027","phase":"PHASE1","title":"Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"Gritstone bio, Inc.","startDate":"2022-02-28","conditions":"COVID-19, SARS-CoV-2","enrollment":342},{"nctId":"NCT06164119","phase":"NA","title":"Effects of Diet and Osteopathy on Quality of Life and Inflammation in Breast Cancer Patients Under Hormonal Therapy","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2023-12-19","conditions":"Breast Cancer","enrollment":600},{"nctId":"NCT05379218","phase":"NA","title":"RIC in HIE: A Safety and Feasibility Trial","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2022-01-17","conditions":"Hypoxic-Ischemic Encephalopathy","enrollment":32},{"nctId":"NCT03981211","phase":"NA","title":"Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2021-02-12","conditions":"Hepatitis C, Liver Inflammation, Liver Cirrhoses","enrollment":60},{"nctId":"NCT01344200","phase":"PHASE2","title":"CELECOXIB Plasma and Cerebral Spinal Fluid Pharmacokinetics in Children","status":"RECRUITING","sponsor":"Children's Hospital of Eastern Ontario","startDate":"2024-01-29","conditions":"Pharmacokinetics of Celecoxib in Children","enrollment":65},{"nctId":"NCT05282628","phase":"NA","title":"I-InTERACT Preterm","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-09-01","conditions":"Pre-Term","enrollment":19},{"nctId":"NCT05757037","phase":"NA","title":"Laser Acupuncture on Irritable Bowel Syndrome in Females","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-03-01","conditions":"Constipation-predominant Irritable Bowel Syndrome","enrollment":50},{"nctId":"NCT03088059","phase":"PHASE2","title":"Biomarker-based Study in R/M SCCHN","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-11-16","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":340},{"nctId":"NCT04890873","phase":"PHASE1","title":"ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity","status":"COMPLETED","sponsor":"ERX Pharmaceuticals","startDate":"2019-10-17","conditions":"Obesity","enrollment":48},{"nctId":"NCT01254942","phase":"NA","title":"Mobilizing Evidence Into Action to Improve Outcomes of Vulnerable Seniors","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2010-12","conditions":"Hip Fractures, Femoral Fractures","enrollment":53},{"nctId":"NCT05084560","phase":"PHASE1","title":"Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug","status":"TERMINATED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2021-12-10","conditions":"Filariasis, Lymphatic, Onchocerciasis","enrollment":30},{"nctId":"NCT05572190","phase":"PHASE1","title":"Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects","status":"UNKNOWN","sponsor":"Elysium Therapeutics, Inc.","startDate":"2022-09-27","conditions":"Acute Pain","enrollment":78},{"nctId":"NCT06030869","phase":"","title":"MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors","status":"UNKNOWN","sponsor":"Tianjin Medical University Second Hospital","startDate":"2020-12-01","conditions":"Refractory Solid Tumors, Next Generation Sequencing","enrollment":400},{"nctId":"NCT03611673","phase":"NA","title":"At-Home Olfactory Training","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-06-02","conditions":"Olfactory Disorder","enrollment":70},{"nctId":"NCT05374954","phase":"PHASE3","title":"Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2022-05-10","conditions":"COVID-19","enrollment":4200},{"nctId":"NCT05850065","phase":"NA","title":"Assessment of Gingival Health Following Rubber-Dam Isolation","status":"UNKNOWN","sponsor":"Marmara University","startDate":"2023-03-10","conditions":"Gingival Recession, Localized","enrollment":30},{"nctId":"NCT04730349","phase":"PHASE1, PHASE2","title":"A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2021-06-03","conditions":"Ependymoma, Ewing Sarcoma, High-grade Glioma","enrollment":15},{"nctId":"NCT05748119","phase":"PHASE1","title":"A Study to Assess the Safety of MEB-1170 in Healthy Subjects","status":"UNKNOWN","sponsor":"Mebias Discovery, Inc","startDate":"2022-11-15","conditions":"Pain","enrollment":72},{"nctId":"NCT05429463","phase":"PHASE3","title":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-11-11","conditions":"Squamous Cell Non-small Cell Lung Cancer","enrollment":250},{"nctId":"NCT04261166","phase":"PHASE1","title":"A Phase I Open Label Study to Assess PK and Safety of Plant Cannabis Extract","status":"COMPLETED","sponsor":"Breath of Life International Pharma Ltd","startDate":"2019-07-24","conditions":"Healthy","enrollment":76},{"nctId":"NCT05082779","phase":"PHASE1","title":"Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159","status":"COMPLETED","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2021-10-26","conditions":"Primary Sclerosing Cholangitis (PSC)","enrollment":79},{"nctId":"NCT04994106","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-07-27","conditions":"Healthy Participants","enrollment":98},{"nctId":"NCT05021666","phase":"PHASE1","title":"A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2020-07-29","conditions":"Healthy Subjects","enrollment":82},{"nctId":"NCT04821674","phase":"PHASE1, PHASE2","title":"Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2021-03-15","conditions":"Covid19","enrollment":142},{"nctId":"NCT05386485","phase":"","title":"Long-term Impact on Cardiopulmonary Function and Quality of Life in Patients Recovered From COVID-19.","status":"UNKNOWN","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2021-08-07","conditions":"COVID-19","enrollment":162},{"nctId":"NCT02963948","phase":"","title":"A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings (\"CDE-EHR-PC\" Study), Phase 3","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2018-02-28","conditions":"Substance Abuse","enrollment":113123},{"nctId":"NCT03805399","phase":"PHASE1, PHASE2","title":"FUSCC Refractory TNBC Umbrella (FUTURE)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-10-18","conditions":"Triple-negative Breast Cancer","enrollment":140},{"nctId":"NCT03768089","phase":"PHASE1, PHASE2","title":"Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-03-20","conditions":"Cystic Fibrosis","enrollment":115},{"nctId":"NCT04798209","phase":"PHASE1","title":"A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2021-01-29","conditions":"Healthy","enrollment":70},{"nctId":"NCT03718780","phase":"NA","title":"Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise","status":"UNKNOWN","sponsor":"Centre Hospitalier Metropole Savoie","startDate":"2019-02-22","conditions":"Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Chronic Heart Failure","enrollment":105},{"nctId":"NCT01655225","phase":"PHASE1","title":"A Study of LY3023414 in Participants With Advanced Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07-31","conditions":"Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma","enrollment":156},{"nctId":"NCT05250440","phase":"","title":"Noninvasive and Dynamic Monitoring the Biological Parameters of Eyes in Different Age Groups","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2022-02-01","conditions":"Myopia","enrollment":240},{"nctId":"NCT04550195","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-09-17","conditions":"Healthy Volunteers","enrollment":26},{"nctId":"NCT03227471","phase":"PHASE1, PHASE2","title":"A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-01-23","conditions":"Cystic Fibrosis","enrollment":225},{"nctId":"NCT05117385","phase":"NA","title":"The Effect of the Consumption of 4 Botanical Extracts on Immunity in Healthy Adults (B-4-Immune)","status":"UNKNOWN","sponsor":"Givaudan France Naturals","startDate":"2021-11-22","conditions":"Healthy Subject, Immunity","enrollment":115},{"nctId":"NCT04422210","phase":"PHASE1","title":"A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-09-22","conditions":"Small Cell Lung Cancer","enrollment":2},{"nctId":"NCT00464646","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2007-05","conditions":"Breast Cancer","enrollment":105},{"nctId":"NCT04622111","phase":"PHASE1","title":"Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers.","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2020-05-27","conditions":"Healthy Volunteers","enrollment":68},{"nctId":"NCT04196179","phase":"PHASE1","title":"ANG-3070 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Angion Biomedica Corp","startDate":"2019-12-17","conditions":"Healthy Volunteers","enrollment":97},{"nctId":"NCT03055936","phase":"PHASE1","title":"Dose-finding Pharmacokinetic Study in Healthy Males","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2017-02-21","conditions":"Healthy Volunteers","enrollment":56},{"nctId":"NCT03822273","phase":"NA","title":"Analgesic Effect of Acupuncture for Patients With Rib Fractures","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2018-03-01","conditions":"Rib Fractures, Acute Pain, Analgesia","enrollment":120},{"nctId":"NCT04008992","phase":"PHASE1","title":"An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-06-18","conditions":"Healthy Participants","enrollment":132},{"nctId":"NCT01515319","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of Y242 in Adult Subjects","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-04","conditions":"Obesity","enrollment":68},{"nctId":"NCT01717326","phase":"PHASE2","title":"A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-07","conditions":"Hepatitis C","enrollment":573},{"nctId":"NCT02374047","phase":"PHASE1","title":"A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects","status":"COMPLETED","sponsor":"Catabasis Pharmaceuticals","startDate":"2015-01","conditions":"Hypercholesterolemia","enrollment":118},{"nctId":"NCT03748979","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-11-21","conditions":"Healthy Participants, Narcolepsy","enrollment":57},{"nctId":"NCT03712553","phase":"NA","title":"Behavioral Science and Hepatitis C Screening Outreach","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-03-15","conditions":"Hepatitis C","enrollment":21493},{"nctId":"NCT04032457","phase":"NA","title":"PAVES Benchmarking Pilot Study of Daily Disposable Contact Lenses","status":"COMPLETED","sponsor":"Vision Service Plan","startDate":"2019-03-15","conditions":"Refractive Errors","enrollment":144},{"nctId":"NCT04183686","phase":"PHASE1","title":"A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2019-11-25","conditions":"Healthy","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tablet: CBD 40 mg"],"phase":"marketed","status":"active","brandName":"B4","genericName":"B4","companyName":"Breath of Life International Pharma Ltd","companyId":"breath-of-life-international-pharma-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"B4 is a medication that works by inhibiting the action of a specific enzyme. Used for Major depressive disorder, Obsessive-compulsive disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}